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Abstract Activation of transcription factor NF-UB is elevated
in several chronic inflammatory diseases and is responsible for
the enhanced expression of many proinflammatory gene pro-
ducts. Extracts from leaves of stinging nettle (Urtica dioica) are
used as antiinflammatory remedies in rheumatoid arthritis.
Standardized preparations of these extracts (IDS23) suppress
cytokine production, but their mode of action remains unclear.
Here we demonstrate that treatment of different cells with IDS23
potently inhibits NF-UB activation. An inhibitory effect was
observed in response to several stimuli, suggesting that IDS23
suppressed a common NF-UB pathway. Inhibition of NF-UB
activation by IDS23 was not mediated by a direct modification of
DNA binding, but rather by preventing degradation of its
inhibitory subunit IUB-K. Our results suggests that part of the
antiinflammatory effect of Urtica extract may be ascribed to its
inhibitory effect on NF-UB activation.
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1. Introduction
Rheumatoid arthritis is an autoimmune disease character-
ized by chronic in£ammation, hyperproliferation of the syno-
vial lining and cartilage destruction. Cytokines, in particular
tumor necrosis factor (TNF), are elevated in the synovial £uid
and presumably involved in the disease process by upregula-
tion of a multitude of in£ammatory mediators [1,2]. The suc-
cess of anti-TNF antibodies in clinical trials underlines that
TNF is a major pathogenic factor in rheumatoid diseases [3].
The de¢nition of TNF as a therapeutic target led to a search
for signaling pathways that control TNF production in rheu-
matoid arthritis.
Transcription factors of the NF-UB family are critical for
the inducible expression of many genes involved in in£amma-
tory responses [4,5]. NF-UB is ubiquitously found as an inac-
tive complex in the cytoplasm bound to its inhibitory subunit
IUB. In the active form NF-UB is a heterodimer which is
frequently composed of a p50 and p65 protein, but also other
subunits such as p52, c-Rel and RelB may participate in com-
plex formation. A large variety of in£ammatory conditions
including bacterial and viral infections, lipopolysaccharide,
cytokines and various forms of stress induce NF-UB activity.
Several lines of evidence indicate that reactive oxygen inter-
mediates (ROIs) serve as second messengers in the activation
pathway of NF-UB [6]. A key event for the activation of NF-
UB is the inducible phosphorylation of the inhibitory subunit
IUB-K on serines 32 and 36. This covalent modi¢cation by IUB
kinases induces the conjunction of IUB to ubiquitin, followed
by a rapid degradation of the inhibitor at the proteasome [7^
9]. The active form of NF-UB then translocates to the nucleus
and binds to regulatory sequences of target genes. Among the
numerous target genes of NF-UB are those encoding in£am-
matory and chemotactic cytokines such as interleukin-1 (IL-
1), IL-2, IL-6, IL-8 and TNF, cell adhesion molecules, major
histocompatibility complex class I molecules, cytokine recep-
tors and proin£ammatory enzymes such as inducible nitric
oxide synthase and cyclooxygenase-2 [4,10]. In many in£am-
matory diseases NF-UB activation is increased leading to the
overexpression of proin£ammatory gene products. In rheuma-
toid arthritis, elevated activation of NF-UB has been detected
in synoviocytes and endothelial cells [11^14]. Furthermore,
using adenoviral expression of IUB-K it has been demon-
strated that TNF production by macrophages is indeed NF-
UB dependent [15].
Another transcription factor which has been implicated in
the pathogenesis of rheumatoid arthritis is activator protein-1
(AP-1). The factor is a dimer composed of protooncogene
products of the Fos and Jun family and plays a major role
in cellular di¡erentiation and proliferation processes [16]. It
has been suggested that increased AP-1 activation may be
responsible for synovial hyperplasia in rheumatoid arthritis
[17,18]. Target genes of AP-1 include the matrix metallopro-
teinases MMP-1 and MMP-3, which are involved in degrad-
ing connective tissues. AP-1 can physically interact with NF-
UB and cooperatively induce cytokine gene expression [19]. It
has also been demonstrated that the activity of both factors is
inhibited by their interaction with the glucocorticoid receptor
[20^22]. Interestingly, the antiin£ammatory action of several
antirheumatic drugs has been attributed to their ability to
modulate NF-UB activation [10].
In the present study, we investigated the e¡ect of leaf ex-
tracts from stinging nettle (Urtica dioica L.) on the activation
of NF-UB. Urtica extracts are used as an adjuvant remedy in
rheumatoid arthritis with a proven therapeutic e⁄cacy. Pre-
viously, it has been shown that Urtica extracts inhibit the
expression of several cytokines as well as eicosanoid forma-
tion in stimulated peripheral blood cells [23,24]. Here we dem-
onstrate that IDS23 (Rheuma-Hek, Strathmann AG), a stand-
ardized extract of stinging nettle leaves, potently suppresses
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the activation of NF-UB in response to several stimuli by the
inhibiting the proteolytic degradation of its inhibitor IUB-K.
IDS23 furthermore exerted an inhibitory e¡ect on the activa-
tion of AP-1, suggesting that at least part of the antirheumatic
e¡ect of Urtica extract may be attributed to its ability to
inhibit proin£ammatory transcription factors.
2. Materials and methods
2.1. Cell culture and reagents
The human T-cell line Jurkat, the macrophage cell line MonoMac6,
the epithelial cell line HeLa and mouse L929 ¢brosarcoma cells were
maintained in RPMI 1640 medium containing 10% FCS, 2 mM glut-
amine and antibiotics. Phorbol myristyl acetate (PMA) and lipopoly-
saccharide (LPS) were obtained from Sigma (Deisenhofen, Germany).
Recombinant TNF was from Knoll AG (Ludwigshafen, Germany).
Extracts of stinging nettle leaves were kindly provided by Strathmann
AG (Hamburg, Germany) as a commercial drug preparation (IDS23,
Rheuma-Hek) and a water-soluble fraction (IDS23/1) [23,25]. For the
preparation of IDS23, one part dried and chopped Urticae dioicae
folia drug was originally extracted with 10 parts of ethanol at 50‡C
for 4 h. For the preparation of the water-soluble fraction IDS23/1,
lyophilized IDS23 was solubilized in culture medium (12.6 mg/ml) by
sonication. After ultracentrifugation at 33 000Ug for 30 min and ster-
ile ¢ltration, the supernatant was used for further experiments. Ac-
cording to gravimetric analysis, 375 Wg of the dry mass of the original
extract IDS23 was solubilized in 1 ml IDS23/1 [23,25].
2.2. Electrophoretic mobility shift assay
Cells were routinely plated at 1^2U106/well in six-well plates and
pretreated for 1 h with stinging nettle extracts, followed by the addi-
tion of the appropriate stimulus. After 1 h total cell extracts were
prepared and used for electrophoretic mobility shift assays (EMSAs)
and Western blot analysis. Extracts were prepared in a high-salt bu¡-
er, incubated with the 32P-endlabeled NF-UB-, Sp1- or AP-1-speci¢c
oligonucleotides (Promega, Heidelberg, Germany) and run on a 4%
non-denaturing polyacrylamide gel as described [7]. To characterize
the NF-UB-DNA complex, supershift analyses were performed using
antibodies against NF-UB subunits (Santa Cruz, Heidelberg, Ger-
many).
2.3. Transfections and luciferase assays
In order to measure the transactivating activity of NF-UB, cells
were transfected by calcium phosphate coprecipitation with a lucifer-
ase reporter gene construct which was controlled by six UB binding
sites fused to the minimal thymidine kinase (tk) promoter. After 16 h
cells were stimulated with the indicated agents for 5 h. Cells were then
lysed in 25 mM glycylglycine, pH 7.8, 1% Triton X-100, 15 mM
MgSO4, 4 mM EGTA, 1 mM DTT, and centrifuged at 13 000Ug at
4‡C for 5 min. 50 Wl of the supernatant was assayed in 100 Wl bu¡er
(25 mM glycylglycine, 15 mM MgSO4, 4 mM EGTA, 15 mM KPi,
pH 7.8, 1 mM DTT, 1 mM ATP) using a luminometer. Following
injection of 100 Wl luciferin (0.3 mg/ml) light emission was recorded as
relative light units.
2.4. Western blotting
To measure the degradation of IUB-K cellular proteins from 2U106
cells were separated on a 12.5% SDS-PAGE under reducing condi-
tions and transferred to nitrocellulose membranes. The membranes
were blocked for 1 h with 5% non-fat dry milk powder in PBS and
incubated for 1 h with an IUB-K-speci¢c rabbit antiserum (Santa
Cruz). Membranes were washed three times with TBS/0.05% Tween-
20 and incubated with peroxidase-conjugated rabbit anti-mouse IgG
for 1 h. Following extensive washing, the reaction was developed by
enhanced chemoluminescent staining.
3. Results
3.1. Urtica extracts are potent inhibitors of NF-UB activation
To investigate the e¡ect of Urtica extracts on NF-UB acti-
vation, we incubated HeLa cells with various concentrations
of a stinging nettle preparation, termed IDS23 (Rheuma-
Hek). Cells were then stimulated with TNF, after which cell
extracts were prepared and analyzed for DNA binding to a
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Fig. 1. Urtica extract inhibits NF-UB DNA binding. A: The e¡ect of IDS23. HeLa cells were treated for 1 h with the indicated concentrations
of IDS23 and then stimulated with 200 U/ml TNF. After 1 h total cell extracts were prepared and analyzed by EMSA. The NF-UB DNA com-
plex is indicated by a ¢lled arrowhead. A faster migrating non-speci¢c complex is marked by a circle. B: Speci¢city and subunit composition
of the NF-UB DNA complex. Total cell extracts from TNF-treated HeLa cells were either left untreated or incubated with antibodies against
the NF-UB subunits p50, p65, c-Rel or with control IgG. Only a section of the autoradiogram is shown. C: The e¡ect of a Harpagophytum
control extract (HE) on NF-UB activity. An extract of Harpagophytum procumbens, which was prepared similarly as IDS23, was used to investi-
gate the speci¢city of Urtica extract for the inhibition of NF-UB activity.
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32P-labeled UB-speci¢c oligonucleotide. As determined by
EMSAs, treatment with TNF caused the appearance of a
novel NF-UB protein-DNA complex (Fig. 1A). A faster mi-
grating, non-speci¢c DNA complex was not a¡ected by the
treatments and provided an internal control for the amount
and integrity of the cell extracts. Pretreatment of cells with
IDS23 dose-dependently inhibited the DNA binding activity
of NF-UB.
Because NF-UB complexes may constitute di¡erent homo-
and heterodimers, we analyzed the composition of the DNA
complex. Antibodies against the NF-UB subunits p50, p65,
and c-Rel were added to an extract of cells stimulated with
TNF. The NF-UB-DNA complex was retarded completely by
anti-p50 (Fig. 1B), whereas the non-speci¢c DNA complex
was not a¡ected. Formation of the upper DNA complex
was also reduced by anti-p65, while anti-c-Rel or control
IgG had no e¡ect. This indicates that the TNF-induced and
IDS23-inhibited NF-UB complex consisted of a p50/p65 het-
erodimer. We further analyzed the e¡ects of an extract from
devil’s claw (Harpagophytum procumbens), which was pre-
pared in a similar manner as IDS23 and taken as a control
extract. At concentrations which e¡ectively inhibited NF-UB
DNA binding in the case of IDS23, Harpagophytum extract
did not interfere with NF-UB (Fig. 1C). This indicates that the
e¡ect on NF-UB activity is speci¢c to Urtica extracts and not
mediated by a ubiquitous plant product.
Previously, it has been demonstrated that the cytokine-sup-
pressing activity of stinging nettle extracts is enriched in a
water-soluble fraction, called IDS23/1 [23^25]. Pretreatment
of HeLa cells with IDS23/1 indeed more strongly inhibited
the formation of the NF-UB-speci¢c DNA complex than
IDS23 (Fig. 2A). To determine whether Urtica extracts spe-
ci¢cally inhibit NF-UB or whether the DNA binding of other
transcription factors was suppressed, we analyzed the extracts
used in Fig. 2A in EMSAs with DNA probes speci¢c for AP-1
and Sp1. As shown in Fig. 2B, AP-1, another transcription
factor implicated in rheumatoid arthritis, was partially inhib-
ited by IDS23/1. In contrast, the activity of Sp1 remained
virtually unchanged (Fig. 2C).
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Fig. 3. Inhibition of NF-UB-controlled gene expression by Urtica ex-
tracts. HeLa cells were transiently transfected with a luciferase re-
porter gene driven by either the minimal tk promoter (tk-Luc; black
bars) or by the tk promoter fused to six NF-UB binding sites (NF-
UB-Luc; gray bars). 16 h after transfection, cells were pretreated
with the indicated concentrations of IDS23 or IDS23/1, stimulated
with TNF and harvested after 5 h of further incubation. Mean val-
ues þ S.D. of NF-UB activity given as relative light units (RLU)
from triplicate experiments are shown.
Fig. 2. The e¡ect of the water-soluble extract IDS23/1 on the DNA binding activity of NF-UB, AP-1 and Sp1. HeLa cells were treated with
IDS23/1 at di¡erent concentrations and analyzed for the DNA binding activity to an oligonucleotide containing a consensus motif for NF-UB
(A), AP-1 (B) and SP-1 (C). In B and C only sections of the autoradiograms are shown. The arrowheads indicate the positions of the speci¢c
DNA complexes. The indicated concentrations of IDS23/1 refer to the solubilized plant material which was determined by gravimetric analysis
as described in Section 2.
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3.2. Urtica extracts inhibit NF-UB-dependent gene expression
The previous experiments demonstrated that Urtica extracts
potently inhibits NF-UB DNA binding. Therefore, we inves-
tigated whether this e¡ect resulted in the functional inhibition
of NF-UB-driven gene expression. To this end, HeLa cells
were transfected with reporter gene constructs which were
controlled either by the minimal tk promoter alone or by a
tk promoter fused to six NF-UB binding sites. Cells were then
pretreated with Urtica extracts and stimulated with TNF.
Treatment of cells with TNF increased NF-UB reporter gene
activity approximately 20-fold (Fig. 3). This activation was
almost completely and dose-dependently prevented by
IDS23 and even more strongly by the water-soluble extract
IDS23/1.
3.3. Urtica extract interferes with a common step of NF-UB
activation
NF-UB can be activated by various stimuli. We asked
whether the e¡ect of Urtica extract was restricted to TNF-
activated HeLa cells or whether the extract was also capable
of inhibiting NF-UB in response to other stimuli in di¡erent
cell types. As shown in Fig. 4A, incubation of Jurkat T-cells
with IDS23/1 dose-dependently inhibited NF-UB induced by
the phorbol ester PMA. An inhibitory e¡ect on NF-UB activ-
ity was also observed in TNF-stimulated L929 ¢brosarcoma
cells (Fig. 4B). Because macrophage-derived cytokines play a
pathogenic role in rheumatoid arthritis, we investigated the
e¡ect of IDS23/1 in MonoMac6 cells which express several
characteristics of mature monocytes. In these cells, LPS
strongly induced NF-UB activation which was likewise im-
paired by Urtica extract (Fig. 4C). It was noteworthy that,
at concentrations used in the EMSAs, IDS23/1 did not mark-
edly compromise the viability of the di¡erent cells (data not
shown). Thus, the results demonstrate that Urtica extracts
inhibit NF-UB in response to diverse stimuli in di¡erent cell
types.
3.4. Urtica extract does not abolish NF-UB DNA binding
activity but inhibits IUB degradation
An explanation for the inhibitory e¡ect of Urtica extracts
could be a direct interference with the DNA binding activity
of NF-UB. It has been shown that the p50 NF-UB subunit
contains redox-active cysteine residues within the DNA bind-
ing domain which are highly susceptible to chemical modi¢-
cation [26]. To analyze the e¡ect of Urtica extracts on the
DNA binding activity, IDS23/1 was directly added to an ex-
tract of TNF-stimulated HeLa cells. Even high concentrations
of IDS23/1 did not prevent DNA binding of active NF-UB in
vitro (Fig. 5A).
A key step of NF-UB activation is the dissociation of its
inhibitor IUB which is mediated through the phosphorylation
and subsequent proteolytic degradation. We therefore incu-
bated Jurkat cells for di¡erent times with PMA in the pres-
ence and absence of IDS23/1 and subsequently analyzed the
degradation of IUB-K by Western blot analysis. Treatment of
cells with PMA led to the rapid degradation of IUB-K, where-
as a protein that reacted non-speci¢cally with the anti-IUB-K
antibody was not a¡ected (Fig. 5B). The degradation of IUB-K
was strongly inhibited by Urtica extract in PMA-stimulated
Jurkat cells (Fig. 5B) as well as in TNF-stimulated HeLa cells
(data not shown). These results suggests that Urtica extract
inhibits NF-UB activation not by directly interfering with its
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Fig. 5. Urtica extract does not directly modify NF-UB DNA binding
(A), but prevents the proteolytic degradation of IUB-K (B). A: An
extract of PMA-stimulated Jurkat cells was treated in vitro with the
indicated concentrations of IDS23/1 and analyzed for NF-UB DNA
binding after 2 h by EMSA. B: Jurkat cells were either left un-
treated (upper panel) or pretreated with IDS23/1 (160 Wg/ml; lower
panel). After 1 h cells were stimulated with PMA for the indicated
times. Cell extracts were analyzed by Western blotting with an IUB-
K-speci¢c antibody. The position of IUB-K is indicated by an arrow-
head. Noteworthy, a slowly migrating protein, which reacted non-
speci¢cally with the antibody, was not a¡ected by the treatments.
Fig. 4. The e¡ect of IDS23/1 on NF-UB activation in response to distinct stimuli. Di¡erent cell lines were incubated for 1 h with the indicated
concentrations of IDS23/1 followed by treatment with the appropriate stimuli for another 1 h. Jurkat T-cells (A) were stimulated with PMA
(50 ng/ml) and L929 ¢brosarcoma cells (B) with TNF (200 U/ml). Macrophage-like MonoMac6 cells (C) were stimulated with LPS (1 Wg/ml).
Total extracts of the di¡erent cell lines were analyzed by EMSAs as described in Fig. 1A.
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DNA binding, but by preventing the degradation of IUB-K or
upstream signaling events.
4. Discussion
Plant remedies have become increasingly popular and are
often preferred to synthetically derived pharmaceuticals. It is
therefore of interest to determine their active components and
to elucidate their molecular mechanisms of action. In the
present study we show that leaf extracts from stinging nettle,
which are used in the treatment of rheumatoid arthritis, po-
tently inhibit transcription factor NF-UB. An inhibitory e¡ect
is demonstrated in di¡erent cell types including T-cells, mac-
rophages, ¢brosarcoma and epithelial cells, as well as in re-
sponse to several stimuli, suggesting that Urtica extracts in-
terfered with a common target in the NF-UB pathway. In this
respect, we show that Urtica extracts stabilize the inhibitor
IUB-K by preventing its proteolytic degradation. Since in£am-
matory processes are strictly dependent on NF-UB activity,
our results suggest a molecular basis for the antiin£ammatory
e¡ects of Urtica extracts.
Recent studies have shown that NF-UB activity is elevated
in rheumatoid arthritis, particularly in the synovial lining and
endothelial cells [11^14]. NF-UB controls the expression of
numerous proin£ammatory gene products including cyto-
kines, molecules involved in endothelial cell adhesion and
antigen presentation as well as in£ammatory enzymes such
as cyclooxygenase II and inducible nitric oxide synthase
[4,10]. It has been demonstrated that TNF expression in mac-
rophages is NF-UB-dependent, because adenoviral infection
with IUB-K strongly inhibited TNF production in rheumatoid
joint cultures [15]. Thus, by decreasing transcription of these
various proin£ammatory genes in concert NF-UB inhibition
should modulate several aspects of in£ammation.
Besides NF-UB, we show that transcription factor AP-1
may be an additional target of Urtica extracts. AP-1 is a
complex of the Fos and Jun protooncogene products and
has been implicated in the hyperplasia of synovial tissues
[17]. Target genes of AP-1 include the matrix metalloprotein-
ases MMP-1 and MMP-3 which play a major role in the
degradation of cartilage matrix molecules. Recently, it could
be demonstrated that inhibition of AP-1 activity by antisense
approaches prevented collagen-induced arthritis in an animal
model [18].
Activation of NF-UB requires the phosphorylation and sub-
sequent proteolytic degradation of IUB by the proteasome
pathway [7]. The precise molecular target of Urtica extracts
remains to be investigated. We provide evidence that Urtica
extracts do not interfere with NF-UB DNA binding, but in-
hibit the proteolytic degradation of IUB. This inhibition may
be the result of a direct prevention of IUB degradation or the
inhibition of IUB kinases or further upstream signaling mole-
cules. The inhibition of NF-UB may be ascribed to an anti-
oxidant property of Urtica extract, as intracellular ROI for-
mation is essential for NF-UB activation in response to
various stimuli [6]. It has been reported that certain £avonoids
and phenol carbon acids such as quercetin and curcumin in-
hibit NF-UB activation presumably by an antioxidant mech-
anism [27,28]. The main phenolic ingredient in Urtica extracts
is ca¡eic malic acid, which suppresses eicosanoid formation
but, compared with Urtica extract, is rather ine¡ective in pre-
venting cytokine production in peripheral blood cells [23,25].
Thus, whether £avonoids or unrelated substances in Urtica
extracts mediate the NF-UB inhibitory e¡ects remains to be
shown. Other naturally occurring compounds which potently
inhibit NF-UB activation are plant sesquiterpene lactones or
gliotoxin [29^31]. It is interesting to note that several drugs
traditionally used in antirheumatic therapy, including sulfosa-
lazine, salicylates, glucocorticoids and gold compounds, exert
at least part of their antiin£ammatory action by interfering
with the NF-UB pathway [20,21,32^34]. The inhibitory e¡ect
on NF-UB activation may therefore provide a simple means to
identify the active antirheumatic compound in Urtica extracts.
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